BioLineRX Ltd. · TASE:BLRX
BioLineRX — Investor Presentation (September 2014)
37 slides from BioLineRX's investor presentation, September 2014

Slide 1: Company Presentation
Company Presentation September 2014

Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains "forward-looking statements." These statements include words like "may," "expects," "believes," “plans,” “scheduled," and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and u

Slide 3: BioLineRx - General
BioLineRx - General • Founded in 2003 by Teva and other key players in Israeli Life Sciences industry • Bridge “development gap” for Israeli assets – Leverage carefully selected early-stage technology, primarily at academia level, following proof of concept in animals (at a minimum) – Invest 3-6 yea

Slide 4: BioLineRx Value Proposition
BioLineRx Value Proposition Extensive deal-flow funnel • Outstanding access to early assets via expert in-licensing team constantly monitoring life science innovations in Israel and abroad • In-licensing efforts guided by open dialogue with R&D and BD divisions Expedited development • Multidisciplin

Slide 5: Long Term Relationships with Israeli Institutions
Long Term Relationships with Israeli Institutions Technion Rambam Medical Center Academic Institutes Haifa Tel Aviv University Medical Centers Sheba Medical Center Tel-Aviv Hebrew University Rehovot Jerusalem Be’er Sheva Hadassah Medical Center Weizmann Institute Ben-Gurion University Sourasky Medic

Slide 6: Main Pipeline Assets
Main Pipeline Assets Pre-Clinical Partners PROJECT INDICATION LEAD DEVELOPMENT PROGRAMS AML Stem cell mobilization CML BL-7010 Celiac disease ADDITIONAL DEVELOPMENT PROGRAMS Skin lesions Inflammatory bowel disease Severe asthma/allergies BL-1110 Neuropathic pain/scleroderma PROGRAMS PARTNERED OR IN

Slide 7: Lead Development Programs
LEAD DEVELOPMENT PROGRAMS 7

Slide 8: BL-8040: Best-in-class CXCR4 antagonist for hematological cancers
BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF HEMATOLOGICAL CANCERS 8

Slide 9: BL-8040 Highlights
BL-8040 Highlights • Indications: Acute myeloid leukemia (AML) & other hematological cancers – Orphan designation received from FDA for both AML and stem-cell mobilization • Mode of Action: CXCR4 antagonism – CXCR4 over-expressed in >70% of tumors, and correlates with disease severity. • Status: Pha

Slide 10: AML – Treatment and Unmet Medical Need
AML – Treatment and Unmet Medical Need • AML is most common acute leukemia in adults – Over 60,000 new cases recorded worldwide in 2010, growing to 130,000 by 2020 – 14,000 cases of AML diagnosed in the US in 2012 – Majority of AML patients relapse and require repeated treatment cycles • AML has poo

Slide 11: BL-8040 Mechanism Of Action
BL-8040 Mechanism Of Action • Binds CXCR4 with high affinity (1-2 nM) • Maintains extended inhibition of CXCR4 through long receptor occupancy (>24 hours) • Works as inverse agonist of CXCR4 • Induces apoptosis of tumor cells dependent on CXCR4 for survival • Increases sensitivity to anti-cancer age

Slide 12: BL-8040 Superiority to Mozobil
BL-8040 Superiority to Mozobil Mobilization BL-8040 12 mg/kg Mozobil 3.2 mg/kg Number of Neutrophils Time post BL-8040/Mozobil injection Cell Death 12

Slide 13: Other Evidence of BL-8040's Superior Anti-Cancer Effect
Other Evidence of BL-8040’s Superior Anti-Cancer Effect BL-8040 (formerly BKT140) inhibits proliferation of Ramos cells compared with Mozobil (AMD3100) and BMS-936564 (MDX-1338) * Study was conducted by scientists from BMS * Kuhne MR, Clinical Cancer Research, 2012 13

Slide 14: Summary of BL-8040 vs. Competitors
Summary of BL-8040 vs. Competitors BL-8040 Mozobil BMS-936564 (BKT-140) (Plerixafor/AMD3100) (MDX1338) Affinity with CXCR4 1-2 nM 84 nM 5nM MOA Inverse agonist Antagonist (partial agonist) Antagonist Extracellular domains in the Trans-membrane regions in Extracellular domains in the CXCR4 Binding si

Slide 15: BL-8040 Platform – Clinical Development Program
BL-8040 Platform – Clinical Development Program Pre-Clinical Phase I Phase II Phase III PROTOCOL INDICATION HEMATOLOGICAL MALIGNANCIES BL-8040.01 R/R AML Ongoing BL-8040.03 CML Investigator-initiated study STEM CELL MOBILIZATION BKTSC001 MM SC MOBILIZATION Completed BL-8040.02 SINGLE AGENT SC MOBILI

Slide 16: Phase IIa - Treatment of r/r AML patients
Phase IIa - Treatment of r/r AML patients A phase IIa, multicenter, open-label study designed to evaluate safety and efficacy profile of repeated escalating doses of BL-8040 in adult subjects with relapsed or refractory acute myeloid leukemia Study design: – Dose escalation phase – 3+3 design, up to

Slide 17: Partial Results in AML Phase II Study
Partial Results in AML Phase II Study • Safe at all doses tested to date (0.5, 0.75 and 1mg/kg) • Substantial mobilization of cancer cells from BM to peripheral blood • Evidence for robust effect of cancer cell death Peripheral blood sample apoptosis assay • Completion of study expected in early 201

Slide 18: BL-8040 Summary
BL-8040 Summary • CXCR4 is a validated target • BL-8040 has robust mobilization activity and apoptosis – Validated in preliminary data from Phase II study in AML, and Phase I/II study in multiple myeloma – BL-8040 has very favorable profile in comparison with leading CXCR4 antagonists • BL-8040 is a

Slide 19: BL-7010: Novel Gliadin Binding Polymer for Celiac Disease
BL-7010: NOVEL GLIADIN BINDING POLYMER FOR CELIAC DISEASE 19

Slide 20: BL-7010: Polymeric Binder for Celiac Disease
BL-7010: Polymeric Binder for Celiac Disease • Indication: Celiac disease • Mode of Action: Non-absorbable polymer with high affinity to gliadins (immunogenic peptides contained in gluten) • Status: Phase I/II ongoing • Product Highlights – Prevents pathological damage to small intestine – Non-absor

Slide 21: Celiac Disease – Large Unmet Medical Need
Celiac Disease – Large Unmet Medical Need • 1% of world’s population suffers from celiac disease – Number underestimated due to lack of awareness/diagnostic tools • Market projected to reach $8 billion by 2019 • No current pharmacological agents approved for celiac – Only treatment option is life-lo

Slide 22: BL-7010 Prevents Formation of Gliadin's Immunogenic Peptides
BL-7010 Prevents Formation of Gliadin’s Immunogenic Peptides Gluten Gluten BL-7010 Copolymer of sodium styrene sulfonate (SS) and 2-hydroxyethyl methacrylate (HEMA) Gliadin Enterocytes BL-7010 demonstrates distinguished specificity towards gliadin Small intestinal damage with loss of absorptive vill

Slide 23: BL-7010 Maintains Normal Structure of GI
BL-7010 Maintains Normal Structure of GI Model: HLA-DQ8/HCD4 transgenic male mice sensitized to gliadin non-sensitized Gluten-sensitized Gluten-sensitized mice mice mice + BL-7010 Villus-to-crypt ratio 5.96 ± 1.23 2.58 ± 0.43 4.89 ± 1.51 23

Slide 24: BL-7010 Clinical Program Overview
BL-7010 Clinical Program Overview • Phase I/II study in celiac patients – Consists of 2 parts: – Single ascending dose – 14 days repeated administration – Safety endpoints – 3 times per day – No efficacy endpoints – Safety w/o efficacy endpoints – Assessment of systemic exposure – Assessment of syst

Slide 25: BL-7010 Clinical Program Overview (cont.)
BL-7010 Clinical Program Overview (cont.) • Pivotal study in celiac patients expected to begin H1 2015 – 6-week repeated oral administration – Efficacy endpoints (primary and secondary) and safety endpoints • A pre-IND meeting with FDA is expected to take place in H1 2015 25

Slide 26: BL-7010 Summary
BL-7010 Summary • Celiac disease is a huge unmet medical need – There are only a handful of clinical-stage programs in development • BL-7010 has a unique MOA – High-molecular-weight polymers – High affinity to gluten – Secreted through feces • Currently in Phase 1/2 pilot study – Compound is well to

Slide 27: BL-1040: First-in-class myocardial implant
BL-1040: FIRST-IN-CLASS MYOCARDIAL IMPLANT FOR PREVENTION OF VENTRICULAR REMODELING FOLLOWING AMI Out-licensed to Bellerophon (f/k/a Ikaria) and being developed as Bioabsorbable Cardiac Matrix (BCM) 27

Slide 28: BL-1040 Highlights
BL-1040 Highlights • Indication: Cardiac remodeling post-AMI • Mode of Action: Provides support to ischemic tissue during healing • Status: CE Mark registration trial – completion expected in mid-2015 • Device designation (including FDA) • Partnered with Bellerophon BCM (f/k/a Ikaria) – Total deal s

Slide 29: Unmet Medical Need
Unmet Medical Need Vessel occlusion Tissue damage Successfully treated with PCI and stents No sufficiently effective treatment for myocardial damage 29

Slide 30: How Does BL-1040 Work?
How Does BL-1040 Work? Arterial injection deposits Porcine AMI model, day 60 material into infarcted tissue Untreated BL-1040 Turns from liquid to gel on contact with infarcted tissue L L V V Gel-like scaffold provides mechanical support to damaged tissue • Dilated left ventricle • Normal size left

Slide 31: Promising Results from Pilot Study
Promising Results from Pilot Study • Designated as device by regulatory authorities (including FDA) • Pilot study in Europe – completed January 2010 – 27 patients, safety and preliminary efficacy in patients with primary MI at high risk for LV remodeling • 9 sites: 6 in Germany, 3 in Belgium • Trial

Slide 32: BL-1040 Pivotal Clinical Development Program
BL-1040 Pivotal Clinical Development Program Pivotal CE Mark Registration trial progressing at full steam • Placebo controlled, total enrollment ~300 patients, six-month follow- up • ~80 sites currently active in nine countries (including 15 sites in US) • >200 patients enrolled to date • Endpoints:

Slide 33: BL-1040 Summary
BL-1040 Summary • Huge unmet medical need – >$1 billion market • Designated as device in both US and Europe • Pilot study successfully completed – No safety or tolerability issues after six months of follow-up – Promising efficacy in comparison to historical data • CE mark registration study progres

Slide 34: Corporate
CORPORATE 34

Slide 35: Financial and Corporate Summary
Financial and Corporate Summary Strong cash position • $33.1 million as of June 30, 2014 • Funds operational capital through end of 2016 • Expect to reach several value inflection points during this time Capital structure • Traded on NASDAQ and TASE (Symbol: BLRX) • 34 million shares outstanding; 40

Slide 36: Major Milestones over next 12 Months
Major Milestones over next 12 Months 2014 BL-7010 (Celiac Disease) phase 1/2 completion BL-8040 (SC Mobilization) phase 1 initiation √ BL-8040 (AML) phase 2 partial results* BL-8040 (CML) phase 1/2 study initiation BL-1040 (AMI) complete CE mark study enrollment BL-8040 (SC Mobilization) phase 1 com

Slide 37: Bench1o Bedoideto Patner
Bench1o Bedoideto Patner BIOLINEM >< 37
Source: Internet Archive copy of biolinerx.com
More decks from BioLineRX Ltd.
Investor Presentation (July 2026)39 slides · July 2026
Q1 2026 Earnings Presentation28 slides · May 27, 2026
Technical Presentation (December 2020)14 slides · Dec 16, 2020
Technical Presentation (December 2020)49 slides · Dec 16, 2020
Investor Presentation (February 2019)31 slides · Feb 4, 2019
Investor Presentation (October 2018)30 slides · Oct 1, 2018